• SHARE

Modified vaccines targeting new variants of the coronavirus won't require domestic clinical trials if the production process and handling of the shots are similar to those of the original authorized vaccine, the nation’s medicine regulator has said.

Drugmakers would still need to submit data from clinical trials overseas that shows immune response to the variants when they apply for Japanese approval, the Pharmaceuticals and Medical Devices Agency (PMDA) said in a statement this week.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)